Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Robert I. Haddad et al.|Journal of Clinical Oncology|2016Cited by 859
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Hyunseok Kang et al.|New England Journal of Medicine|2020Cited by 766
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Robert I. Haddad, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2017Cited by 653
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012Ranee Mehra, Robert I. Haddad, Tanguy Y. Seiwert et al.|British Journal of Cancer|2018Cited by 457
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I. Haddad, Ranee Mehra, Tanguy Y. Seiwert et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 96